[Mutation-specific treatments for Duchenne muscular dystrophy].

Area of Science:

• Genetics
• Molecular Biology
• Neurology

Background:

• Duchenne muscular dystrophy (DMD) is a common inherited muscle disease caused by dystrophin deficiency due to gene mutations.
• Current treatments for DMD are limited, with progressive muscle wasting leading to early mortality.

Purpose of the Study:

• To review promising treatment strategies for correcting dystrophin gene mutations in DMD.
• To summarize approaches like exon skipping and read-through induction.

Main Methods:

• Antisense oligonucleotides (ASOs) are used to induce exon skipping, correcting out-of-frame mutations to in-frame.
• Read-through agents like gentamicin or PTC124 are explored for nonsense mutations.

Main Results:

• Successful induction of dystrophin production in a DMD patient using ASOs targeting exon 19 for an exon 20 deletion.
• PTC124 is currently undergoing clinical trials for nonsense mutation-induced DMD.

Conclusions:

• Exon skipping with ASOs shows potential for treating DMD patients with specific deletion mutations.
• Read-through therapies offer another avenue for treating DMD caused by nonsense mutations.